Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib plus Icotinib in EGFR-mutated NSCLC
NCT05007938Phase 2Active, not recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of befotertinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Aug 2021; status: active, not recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05007938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007938.